Argenx SE

Overview

Argenx SE (Argenx) is a human antibodies developer. The company offers autoimmunity and oncology products. Its wholly owned product candidates include ARGX-113, ARGX-110, ARGX-117 and ARGX-111. Argenx partnered product candidates are ARGX-109, ARGX-112, ARGX-115 AND ARGX-116. The company offers treatment for T-cell lymphoma, nasopharyngeal cancer, chronic myelogenous leukemia and MET amplified cancer among others. It offers product such as Efgartigimod, Cusatuzumab and candidates to myasthenia gravis immune thromocytopeniapemphigus valgaris chronic auto immune diseases, T cell lymphoma, acute myeloid leukemia and blood cancer. Argenx products are used for the treatment of inflammatory and autoimmune diseases. The company develops antibodies using its proprietary technology platforms such as NHance, simple antibody technology, and others. It operates offices in the Netherlands and Belgium. Argenx is headquartered in Breda, the Netherlands.
Key Stats
Address
Willemstraat 5 BREDA 4811 AH Netherlands
Headquarters

Netherlands

Contact

31 76 3030488

No of Employees

336

Industry

Pharmaceuticals and Healthcare

Ticker Symbol & Exchange​

ARGX [ENXTBR]

Revenue (2020)

$43 m

-47.7% (2020 vs 2019)
Net Income (2020)

$-623 m

-224.6% (2020 vs 2019)
Net Profit Margin

-1452 %

-521.8% (2020 vs 2019)
Market Cap *

$17,035 m

EPS *

$-13.7

  *Note: Ratios based on the share price as of 8-September-2021, in absolute numbers and US$.

Peer Comparison

Key Parameters Argenx SEPharming Group NV
Key Information
Headquarters Netherlands Netherlands
Headquarter City BREDA LEIDEN
Headquarter State/Province - -
No. of Employees 336 262
Entity Type Public Public

Products & Services

Argenx operates as a biotechnology company. Key products offered by the company include the following:

Products
  • Products:
  • Pipeline Products
  • ARGX-113
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
Brands
  • SIMPLE Antibody
  • NHance
  • ABDEG
  • Rutrum Elit
Key Financial Charts
Sales Growth
Operating Margin
Net Income Growth
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets

Employees

Name Position Board Since Age Biography
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
2021 Contracts/Agreements In January, the company and Zai Lab Limited entered into a license agreement to develop…
2021 Contracts/Agreements In April, the company along with IONTAS Limited, and FairJourney Biologics entered into a collaboration…
2020 Contracts/Agreements In November, the company entered into an agreement to acquire Priority Review Voucher from Bayer…
2019 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2019 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2017 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam

Locations


Argenx BVBA

Address

Building C, Industriepark Zwijnaarde 7, Zwijnaarde
Belgium

Telephone

32 9 3103400

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target
07 Jun 2021 Cilag (Janssen) Terminates Collaboration and Licensing Agreement with Argenx Licensing Agreement Cilag GmbH International Argenx SE
20 Apr 2021 argenx Enters into Licensing Agreement with Elektrofi Licensing Agreement Argenx SE Elektrofi Inc
12 Apr 2021 FairJourney Biologics and IONTAS Enter into Collaboration with argenx Partnership IONTAS Ltd; FairJourney Biologics SA; Argenx SE
30 Mar 2021 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
01 Mar 2021 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
01 Feb 2021 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit

Jobs Overview

53

Active Jobs

12

Posted

14

Closed

Job Trends

Latest Jobs

Job title Company Country
Brand Director EMEA Argenx SE Belgium
Scientist R Argenx SE Belgium
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar